About

Donald R.J. Singer, BMedBiol, MD, FRCP, FBPhS

Donald R.J. Singer, BMedBiol, MD, FRCP, FBPhS
Co-Opt
European Association for Clinical Pharmacology and Therapeutics

Professor Donald Singer is a clinical pharmacologist interested in drug discovery, prevention and treatment of disease, and improving safety and effectiveness in use of medicines. He is also interested in promoting better public understanding of the benefits and risks of medicines and in the regulation of medicines. He is a member of the panel of experts of the European Medicines Agency and has given expert advice to the Commission on Human Medicines. A member since 2013 of the Healthcare Professionals' Working Party of the European Medicines Agency, he is involved in EMA current projects on minimizing risk from medicines.

He is President of the UK Fellowship of Postgraduate Medicine for which in 2012 he co-founded the Elsevier published journal, Health Policy and Technology. He is a member of the Executive Committee of the European Association of Clinical Pharmacology and Therapeutics (2011-2015 Secretary), which supports scientific and educational exchange for over 4,000 clinical pharmacologists from 34 countries. He co-authors the prescribing and safety guide, Pocket Prescriber, the 8th edition of which was published by Taylor & Francis in August 2015. He is a former member of the Councils of the British Pharmacological Society, of the British Hypertension Society and the British Microcirculation Society.

International consultancy includes advice on clinical pharmacology and safety systems for medicines as a Yale School of Medicine Faculty member within the seven-year Human Resources for Health USAID- and CDC-supported programme in Rwanda.

Health Technology Assessment
He was a Clinical Pharmacologist member of the Pharmaceuticals Panel of the NHS Health Technology Assessment Programme (2009-2013), and a Clinical Pharmacologist member of the new Panel for Primary Care, Community and Preventive Interventions (2013-2014). HTA is a key component of NHS R&D strategy. HTA considers clinical, personal, social, ethical and financial evaluation of methods, devices (including drugs) and techniques used to promote health and to prevent and treat disease before these technologies are adopted in clinical practice. The Pharmaceuticals Panel assessed topic suggestions involving drugs (including drug prescribing) in primary and secondary care. The new PCCPI extended these and other approaches to the community and interface organisations.